Simultaneous Radiotherapy with Continued use of Osimertinib in EGFR-mutated Adenocarcinomas of the Lung

被引：0
|
作者：
Syunyaeva, Z. [1 ,2 ]
Kauffmann-Guerrero, D. [3 ,4 ]
Kahnert, K. [5 ,6 ]
Behr, J. [7 ]
Tufman, A. [8 ,9 ]
机构：
[1] Klinikum Univ Munchen, Med Klin & Poliklin 5, Sekt Pneumol & Thorakale Onkol, Munich, Germany
[2] Lungentumorzentrum Munchen, Munich, Germany
[3] Univ Munich Lmu, Comprehens Pneumol Ctr, Dept Internal Med 5, Munich, Germany
[4] German Ctr Lung Res Dzl, Munich, Germany
[5] Ludwig Maximilians Univ Munchen, Dept Internal Med Resp Med & Thorac Oncol 5, Thorac Oncol Ctr Munich, Munich, Germany
[6] German Ctr Lung Res Dzl Cpc M, Munich, Germany
[7] Klinikum LMU Munchen, Med Klin & Poliklin 5, Comprehens Pneumol Ctr, Munich, Germany
[8] Ludwig Maximilian Univ Munich, Munich, Germany
[9] Ludwig Maximilian Univ Munich, Thorac Oncol Ctr, Div Resp Med & Thorac Oncol, Dept Internal Med 5, Munich, Germany
来源：
PNEUMOLOGIE | 2020年 / 74卷
关键词：
D O I：
10.1055/s-0039-3403365
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
P527
引用
收藏
页码：S133 / S133
页数：1
相关论文
共 50 条
  • [1] Osimertinib in EGFR-Mutated Lung Cancer REPLY
    Herbst, Roy S.
    Wu, Yi-Long
    Tsuboi, Masahiro
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (07): : 675 - 676
  • [2] Adjuvant therapy with Osimertinib in resectable EGFR-mutated lung cancer
    Gassa, Asmae
    Ozkan, Filiz
    Alakus, Hakan
    Bruns, Christiane
    ONKOLOGE, 2021, 27 (02): : 172 - 173
  • [3] Osimertinib in Resected EGFR-Mutated NSCLC
    Tsuboi, Masahiro
    Herbst, Roy S.
    Wu, Yi-Long
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 389 (14): : 1341 - 1342
  • [4] Osimertinib with Chemotherapy in EGFR-Mutated NSCLC
    van Doorn-Khosrovani, Sahar Barjesteh van Waalwijk
    Badrising, Sushil K.
    Burgers, Sjaak
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 390 (05): : 478 - 479
  • [5] Osimertinib in EGFR-Mutated Advanced NSCLC
    Revannasiddaiah, Swaroop
    Devadas, Santhosh K.
    Maka, Vinayak V.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (19): : 1864 - 1864
  • [6] Unique microRNA-profiles in EGFR-mutated lung adenocarcinomas
    Bjaanaes, Maria Moksnes
    Halvorsen, Ann Rita
    Solberg, Steinar
    Jorgensen, Lars
    Dragani, Tommaso A.
    Galvan, Antonella
    Colombo, Francesca
    Anderlini, Marco
    Pastorino, Ugo
    Kure, Elin
    Rresen-Dale, Anne-Lise B.
    Brustugun, Odd Terje
    Helland, Aslaug
    INTERNATIONAL JOURNAL OF CANCER, 2014, 135 (08) : 1812 - 1821
  • [7] PNEUMONITIS RISK FOLLOWING COMBINED OSIMERTINIB AND THORACIC RADIOTHERAPY IN EGFR-MUTATED NONSMALL CELL LUNG CANCER
    Mak, David Y.
    Nusrat, Humza
    Yan, Michael
    Parmar, Ambika
    Poon, Ian
    Ung, Yee
    Tsao, May
    Warner, Andrew
    Cheung, Patrick
    Louie, Alexander V.
    RADIOTHERAPY AND ONCOLOGY, 2023, 186 : S12 - S12
  • [8] Afatinib After Progression on Osimertinib in Patients with EGFR-Mutated Lung Adenocarcinoma
    Aredo, J.
    Wakelee, H. A.
    Neal, J.
    Padda, S.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S619 - S619
  • [9] Achievement of pathological complete response with osimertinib for EGFR-mutated lung adenocarcinoma
    Fujita, Yasuhiro
    Take, Nobuyuki
    Shinohara, Shinji
    Mori, Masataka
    Kanayama, Masatoshi
    Takenaka, Masaru
    Kuroda, Koji
    Shimajiri, Shohei
    Tanaka, Fumihiro
    GENERAL THORACIC AND CARDIOVASCULAR SURGERY CASES, 2023, 2 (01):
  • [10] Adjuvant Osimertinib Improves Overall Survival in EGFR-Mutated Lung Cancer
    Kim, Edward S.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2023, 21 (07) : 370 - 370
12345